New Pediatric Dosage Form and Label Changes for Reyataz (Atazanavir)
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label."
The updated labeling for atazanavir is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on atazanavir
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Department of Health | Health | HIV AIDS | Infectious Diseases | Pediatrics | Reyataz | Websites